Five minutes with… Eva Kabir
Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.
Cutting back the thickets of Biosimilars
The Biologics market has changed dramatically since the introduction of the Biologics Price Competition and Innovation Act in 2014 in the US. The act provides a pathway for similar biologics to make it to market safely, cost-effectively, and legally.
BGI secures appeal trial over Illumina DNA verdict
Chinese genome sequencing company BGI has been given the go-ahead to appeal an English High Court ruling in an ongoing lawsuit launched by competitor Illumina regarding its DNA sequencing patents.
Five minutes with… Irena Royzman
Since the formalisation of the new Biologics Price Competition and Innovation Act framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.
Nevro escalates patent dispute with Boston Scientific
Medical device maker Nevro has hit competitor Boston Scientific with a lawsuit for allegedly infringing patents that cover a spinal cord stimulation technology.
Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.
COVID-19 spurs medical and pharma rise in ‘Top 100 Global Innovators’ report
Innovation by medical and pharma sectors has increased over the past year in the wake of the pandemic, a new report by IP services company Clarivate has confirmed.
Bayer sues over syringes used in CT scans
Bayer Healthcare is suing medical devices manufacturer Ecomed Solutions over allegedly patent-infringing syringes.
AbbVie settles longstanding trade secret dispute with Evolus
AbbVie and its Korean partner Medytox have settled a trade secret dispute with competitor Evolus over the sale of a rival botox competitor drug Jeuveau.
Fed Circuit cancels skin cancer detection patent
The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.
